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Abstract: The objective of the present study was to develop n-propyl gallate-loaded solid lipid
nanoparticles (PG-SLNs) in a hydrogel (HG) formulation using Transcutol-P (TC-P) as a permeation
enhancer. Modified solvent injection technique was applied to produce optimized PG-SLNs via the
Quality by Design approach and central composite design. The in vitro mucoadhesion, scavenging
activity, drug release, permeation studies of PG from PG-SLNs-loaded HG were evaluated under
simulated nasal conditions. Compared with in vitro release behavior of PG from SLNs, the drug
release from the PG-SLNs-loaded HG showed a lower burst effect and sustained release profile. The
cumulative permeation of PG from PG-SLNs-loaded HG with TC-P was 600 µg/cm2 within 60 min,
which is 3–60-fold higher than PG-SLNs and native PG, respectively. Raman mapping showed that
the distribution of PG-SLNs was more concentrated in HG having lower concentrations of hyaluronic
acid. The scavenging assay demonstrated increased antioxidant activity at higher concentrations of
HG. Due to enhanced stability and mucoadhesive properties, the developed HG-based SLNs can
improve nasal absorption by increasing residence time on nasal mucosa. This study provides in vitro
proof of the potential of combining the advantages of SLNs and HG for the intranasal delivery
of antioxidants.
Keywords: hydrogel; SLNs; nose-to-brain delivery; mucoadhesion; quality by design; antioxidant
activity
1. Introduction
In the past few years, the intranasal administration route has gained considerable
interest since it provides a non-invasive method to bypass the blood–brain barrier (BBB).
Most regions in the central nervous system (CNS) can be directly reached along the olfactory
and trigeminal nerves by intranasal administration of drugs. This intranasal administration
route is broadly innervated by the olfactory nerve, which is localized in the epithelial
tissue of the nasal olfactory mucosa and respiratory mucosa [1]. Various studies provide
promising data for the potential of nose-to-brain delivery pathway in the treatment of CNS
diseases such as brain tumors, Parkinson’s disease and Alzheimer’s disease [2,3].
Nose-to-brain delivery is considered very effective for many CNS active drugs that
have limited administration because of low bioavailability through other delivery routes
including paclitaxel, levetiracetam, cephalexin, dopamine, estrogen or even nerve growth
factor-1 [4]. Limited brain uptake can be achieved in numerous intranasally applied com-
pounds from conventional formulations, including chemotherapeutics and antineoplastic
agents, due to their low permeability, enzymatic degradation and rapid elimination by
mucociliary clearance from the nasal cavity [5–7]. To hurdle these obstacles, the application
of nano drug delivery systems can be a suitable tool.
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Lipid nanoparticles, including liposomes, niosomes, nanoemulsions and solid lipid
nanoparticles (SLNs), are among the most promising drug delivery systems because of
their biocompatible nature [8–10]. Moreover, these nanosystems can provide protection
of the embedded active pharmaceutical ingredient (API) against efflux transporters (P-
glycoprotein), enzymatic degradation or chemical destabilization at nasal conditions [11].
Compared with conventional lipid nanoparticulate drug delivery systems, active target-
ing has attracted significant attention due to enhanced therapeutic benefits and reduced
undesirable side effects.
Hyaluronic acid (HA), a glycosaminoglycan, is a linear polysaccharide that is com-
posed of β-1,4-D-glucoronic acid and 1,3-N-acetyl-D-glucosamine disaccharides via alter-
nating glycosidic bonds [12–14]. Hydrogels (HG) containing HA have been successfully
developed and evaluated for several promising biomedical applications as carrier systems
in nasal, pulmonary, parenteral, topical and ophthalmic delivery [15,16]. Loading nanopar-
ticles into low molecular weight HA-HG can improve nasal absorption by increasing
residence time on nasal mucosa through enhanced viscosity and mucoadhesive properties.
Improved mechanical stability against degradation and enhanced biochemical functional-
ity of HA can be easily reached using cross-linkers such as glutaraldehyde (GA), divinyl
sulfone, carbodiimide or bisepoxide [17,18]. In addition to the gel-forming properties, HA
can also be applied in targeted drug delivery [19]. In our experiments, GA was applied due
to having high potency to function as a proper cross-linker and because the nasal lining is
fairly resistant to aldehyde toxicity below millimolar concentrations [20].
Propyl gallate (PG) (propyl 3,4,5-tri-hydroxybenzoate) is an ester form of gallic acid,
and propanol functions as a synthetic antioxidant. Previous studies showed that PG has a
high antioxidant capacity, which may contribute to decreasing mitochondrial impairment
and to inhibiting cellular respiration. PG has demonstrated anticancer effects on various
normal and tumor cells that may lead to DNA genotoxicity, cytotoxicity and fragmenta-
tion [21,22]. It has been revealed that PG used along with other anti-tumor agents such
as probiotics was effective in mice for tumor treatment [23]. The PG anticancer activity
can stop cell proliferation, reduce reactive oxygen species production and stimulate the
autophagy of malignant cells [24].
This study aimed to optimize PG containing solid lipid nanoparticles (PG-SLNs)
embedded into chemically linked HA-HG as a suitable delivery system for the intranasal
route. Intranasal administration of PG can be a promising approach for targeted treatment
of brain tumors, e.g., glioblastoma multiforme [25] bypassing the BBB; moreover, this
non-invasive way of administration can be more favorable for patients. A further aim was
to investigate the effect of excipients as a permeation enhancer for Transcutol-P (TC-P) due
to its nontoxicity and biocompatibility and GA as cross-linker for intranasal route. For
the formulation optimization, the Quality by Design (QbD) methodology was applied as
a quality improvement principle that is able to take into account all critical parameters
that have an impact on final product quality, safety and efficacy using a response surface
quadratic model.
2. Results
2.1. Quality by Design Approach and Risk Assessment (RA)
Screening of the quality target product profile (QTPP) was based on previous exper-
imental data and according to the relevant International Conference on Harmonization
(ICH) guidelines (Q8,Q9,Q10,Q11) [26,27]. The QTPP elements in this study were the
route of administration, indication, dissolution and permeability profiles, stability and
brain distribution [28,29]. QTPPs contain the information required by the mentioned ICH
guidelines on the one hand, and the basic assumptions that our product must meet on the
other. Based on the QTPPs, the defined aim was to develop a monodisperse PG-containing
SLN embedded in a HG formulation that is able to enter the central nervous system via the
nose-to-brain pathway as a patient adherence improving drug delivery pathway offering
direct transport to the CNS. Figure S1 shows the relations established between the QTPP-
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CQA (QTPP-critical quality attribute) and the critical process parameters/critical materials
attributes (CPPs/CMA-CQA) elements on a 3-grade scale. During the RA process, the
particle characteristics of the nanoformulation were placed under thorough evaluation as
they are the key elements during the incorporation to an HG formulation.
Based on the interdependence rating and using the software, quantification of these
relations was performed, and severity scores were assigned for each CQA and CPP/CMA
element, as presented in Figure 1.
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element in QbD-driven nanoparticle formulation is to establish the basis for proper parti-
cle size and distribution, as these are the main elements influencing the dissolution and 
permeability profile, which are the first crucial steps in the nasal administration in the 
nasal cavity and through the nasal mucosa. Based on the calculations, it can be claimed 
that material attributes such as the concentration of Tween 80 and cholesterol hold the 
highest risk severity, followed by the temperature at dissolution phase compared with the 
subprocesses, as seen on Figure 1b. The subprocesses might hold low severity due to the 
fact that these are either easily controllable processes or because their main function is to 
Figure 1. Probability rating of CQA (a) and CPP/CMA (b) elements. The Pareto charts are presented
as the calculated severity scores assigned to the ele ents.
The interdependence rating (Figure S1) assigned mostly high-grade scores concerning
the relations of particle characteristics (Z-average, PDI and zeta potential) which is sup-
ported by the higher severity scores in Figure 1a compared with the applicability affecting
risk factors such as muco-adhesivity, viscosity and swelling properties. The key element in
QbD-driven nanoparticle formulation is to establish the basis for proper particle size and
distribution, as these are the main elements influencing the dissolution and permeability
profile, which are the first crucial steps in the nasal administration in the nasal cavity
and through the nasal mucosa. Based on the calculations, it can be claimed that material
attributes such as the concentration of Tween 80 and cholesterol hold the highest risk
severity, followed by the temperature at dissolution phase compared with the subprocesses,
as seen on Figure 1b. The subprocesses might hold low severity due to the fact that these
are either easily controllable processes or because their main function is to achieve the
final dosage form, whilst without the appropriate ratios and proportions of the material
attributes, the nanosystem cannot be formed.
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2.2. Central Composite Design (CCD)
2.2.1. Optimization and Impact of Critical Parameters on Z-Average, Polydispersity Index
(PDI), Zeta Potential
Based on the QbD methodology-based RA process, the design of the experiment was
conducted according to severity scores. The effect of the characteristics with the highest
severity score, i.e., the cholesterol content (A), the Tween 80 content (B) and temperature
(◦C), were investigated on the independent factors: Z-average, PDI and zeta potential in a
15-formulation experiment series presented in Table 1. We incorporated the results into the
software, and as a result, a design expert selected a run (7) depending upon the smallest
size, PDI and the characteristic with more negative zeta potential. The software screened
the optimized trial with the desirability of 0.99 depending on the lowest Z-average, PDI
and more negative zeta potential. The optimized PG-SLNs consisted of 1:6 of Tween 80 and
cholesterol. The effects of each individual factor and the combined effect of factors on
studied factors are shown in Figure S2a. It was revealed that at a low amount of cholesterol
(20 mg), the Z-average was slightly higher than set trials where the maximum amount of it
(60 mg) was used. With surfactant addition, the Z-average was less at low concentration of
cholesterol due to lower lipid aggregation because of Tween 80 incorporation.
Table 1. Effect of independent variables (temperature, surfactant, cholesterol) on Z-average, PDI and Zeta potential of















1 45 25 40 150 ± 10 0.30 ± 0.01 −30 ± 8.4
2 20 25 40 220 ± 5.5 0.22 ± 0.02 −29 ± 6.5
3 45 25 40 140 ± 4.5 0.23 ± 0.02 −31 ± 8.4
4 80 10 40 155 ± 5.5 0.25 ± 0.05 −29 ± 8.4
5 45 40 40 500 ± 6.6 0.44 ± 0.07 −5 ± 7.5
6 70 40 20 400 ± 7.8 0.55 ± 0.01 −6 ± 8.5
7 * 70 10 60 120 ± 8.8 0.12 ± 0.08 −38 ± 10.2
8 45 25 40 155 ± 22 0.26 ± 0.09 −29 ± 12
9 45 10 40 200 ± 2.3 0.21 ± 0.08 −29 ± 5.5
10 20 10 20 230 ± 2.4 0.22 ± 0.06 −19 ± 6.5
11 45 25 40 160 ± 40 0.25 ± 0.08 −28 ± 10
12 45 25 40 145 ± 20 0.18 ± 0.05 −28 ± 10.2
13 20 40 60 600 ± 12 0.46 ± 0.01 −4 ± 3.3
14 45 25 20 222 ± 10 0.23 ± 0.02 −20 ± 5.5
15 45 25 60 190 ± 14 0.22 ± 0.02 −19 ± 6.2
* Parameters of optimized formulation.
Even though smaller particle size was obtained at a higher temperature, the tem-
perature effect was not statistically significant. The interaction of individual factors, i.e.,
cholesterol, on particle size, PDI and zeta potential, are also presented in Figure S2b.
The significance of the applied model was evaluated by F-value and p-value. In
the case of particle size analysis, the model F-value of 56.89 implies that the model is
significant. The following equations describe the linear and quadratic relations of the
individual parameters influencing the dependent factors:
Particle size = 160.57 − 23.74A + 144.53B − 60.62C + 16.88AB − 17.97AC − 50.11BC + 26.74A2 + 176.21B2 − 16.67C2 (1)
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In the case of zeta potential, the model F-value of 10.31 implies that the model is
significant. There is only a 0.97% chance that a “model F-value” this large could occur due
to noise. Values of “Prob > F” less than 0.0500 indicate that model terms are significant.
Zeta Potential = −27.42 − 0.8A + 11.08B + 3.45C + 8.7AB − 0.67AC + 2.8BC + 4.78A2 + 8.2B2 − 0.73C2 (2)
In the case of PDI, the model F-value of 9.41 implies that the model is significant.
PDI = 0.24 − 0.01A + 0.0988B + 0.028C + 0.042AB − 0.057AC + 0.026BC − 0.012A2 + 0.075B2 + 0.019C2 (3)
Regarding the particle size, B, C, B2 are significant model terms, while in the case
of the Zeta potential and PDI, B, B2 are significant models. In all three cases, the values
were less than 0.1000, indicating the significance of the applied model. The optimized
PG-SLNs were further evaluated for encapsulation efficiency (EE), percentage yield and
loading capacity (LC). Optimized PG-SLNs resulted in 84 ± 0.47% EE and 60 ± 0.03%
LC. The yield of the PG-SLNs was up to 80 ± 0.1%. Z-average, PDI and zeta potential
were also measured for optimized PG-SLNs. The Z-average of PG-SLNs was reported as
103 ± 46 nm with PDI of 0.16 ± 0.001 and zeta potential of −36 ± 4.78 mV.
2.2.2. XRPD and FTIR Analysis
X-ray powder diffractograms (XRPD) of PG show sharp, characteristic peaks confirm-
ing its crystalline nature (Figure 2a). The results show that the characteristic peaks of PG
(4.1◦, 6.2◦, 25.8◦ and 26.4◦ 2θ) could not be observed in the diffractogram of PG-SLNs,
which shows that the crystalline structure of PG is converted into amorphous form and
also supports the EE measurement data according to the high amount of PG that was
successfully encapsulated into SLNs. In the diffractogram of PG-SLNs, only one peak can
be detected at 5.2◦ 2θ, which corresponds to cholesterol as a carrier base material. These
results of PG-SLNs are in agreement with similar experiments reported in the literature [30].
The FTIR spectra (Fourier-transformed infrared spectroscopy) of the components and the
formulation are presented in Figure 2b. The characteristic peaks of PG including O–H
stretching vibration at 3331 cm−1, C=O stretching of ester at 1539 cm−1, phenol O–H bend-
ing at 1246 cm−1 as well as C–O–C stretching of aromatic ester at 770 cm−1 and 745 cm−1
become unobvious in the spectrum of PG-SLNs, which also indicates the encapsulation of
PG into SLNs. No other remarkable shift was observed in the other spectral regions, which
supports that there is no interaction between SLNs and components.




Figure 2. XRPD diffractogram (a) and FTIR spectra (b) of PG-SLNs and their components. 
2.3. Characterization of Hydrogels 
2.3.1. Evaluation of pH and Drug Contents of Hydrogels 
It has been reported in several previous studies that lysozyme as a physiological na-
sal mucosa enzyme could inhibit specific types of microbes under slightly acidic condi-
tions [31]. Therefore, the pH of an ideal nasal formulation should be in the range of 5.0 to 
6.0 to preserve the physiological microbiological defense [32,33]. The pH of the HA-HGs 
was between 5.2 and 5.9, which is suitable for nasal administration. Drug content of HA-
HGs was 78–82% w/v measured by HPLC, as shown in Table 2. 
2.3.2. Raman Chemical Mapping 
Raman mapping was carried out in order to examine the distribution of PG-SLNs in 
non-cross-linked HA-HGs (SLNs-HGnCL) of different concentrations. For localization of 
nanoparticles, the Raman spectrum of PG-SLNs were set as profile, whose frequency of 
occurrence is shown in the chemical maps (Figure 3). The different colors of the chemical 
map show the relative intensity change of PG-SLNs in the gel structure. Red color indi-
cates strong existence of PG-SLNs, whereas blue color marks those regions of the map 
whose spectral resolution contains different spectra, characteristic for another component. 
The results reveal that the distribution of PG-SLNs is more concentrated in HGs contain-
ing HA in lower concentration (0.5% and 1% w/v), as shown by high relative intensity 
values of the Raman map, whereas in the case of higher HA concentration (2% and 3% 
w/v), PG-SLNs can be found in well-defined packages. 
Figure 2. XRPD diffractogram (a) and FTIR spectra (b) of PG-SLNs and their components.
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2.3. Characterization of Hydrogels
2.3.1. Evaluation of pH and Drug Contents of Hydrogels
It has been reported in several previous studies that lysozyme as a physiological nasal
mucosa enzyme could inhibit specific types of microbes under slightly acidic conditions [31].
Therefore, the pH of an ideal nasal formulation should be in the range of 5.0 to 6.0 to
preserve the physiological microbiological defense [32,33]. The pH of the HA-HGs was
between 5.2 and 5.9, which is suitable for nasal administration. Drug content of HA-HGs
was 78–82% w/v measured by HPLC, as shown in Table 2.
Table 2. Main physicochemical characteristics of hydrogels at various hyaluronic acid concentrations.
HA Content














0.5 5.3 ± 0.2 78 ± 2.5 222.45 ± 0.22 20 * 0.112 0.181
1 5.2 ± 0.3 82 ± 3.3 360 ± 0.33 20 1.88 2.11
2 5.5 ± 0.4 80 ± 1.4 320 ± 0.44 10 14.29 15.45
3 5.9 ± 0.6 79 ± 4.2 340 ± 0.012 1 66.34 157
* After 2 h maximum displacement on agar-mucin plate was already reached.
2.3.2. Raman Chemical Mapping
Raman mapping was carried out in order to examine the distribution of PG-SLNs in
non-cross-linked HA-HGs (SLNs-HGnCL) of different concentrations. For localization of
nanoparticles, the Raman spectrum of PG-SLNs were set as profile, whose frequency of
occurrence is shown in the chemical maps (Figure 3). The different colors of the chemical
map show the relative intensity change of PG-SLNs in the gel structure. Red color indicates
strong existence of PG-SLNs, whereas blue color marks those regions of the map whose
spectral resolution contains different spectra, characteristic for another component. The
results reveal that the distribution of PG-SLNs is more concentrated in HGs containing HA
in lower concentration (0.5% and 1% w/v), as shown by high relative intensity values of the
Raman map, whereas in the case of higher HA concentration (2% and 3% w/v), PG-SLNs
can be found in well-defined packages.
2.3.3. Spreadability and Swelling Studies of Hydrogel
The spreadability values of both cross-linked (SLNs-HGCL) and non-cross linked
(SLNs-HGnCL) SLNs-HGs was investigated. No significant effect of cross-linking was
observed in case of spreadability; SLNs-HGs with different concentrations of HA (0.5, 1,
2 and 3% w/v) showed 222.45 ± 0.22, 360.10 ± 0.33, 320.12 ± 0.44 and 340 ± 0.01 mm2
spreading surface, respectively (Table 2). Values in this range ensure proper spreading
of the hydrogel. The spreadability study showed that the optimized SLNs-HG (1% w/v
HA) resulted in the highest spreading surface [34,35]. Swelling studies were performed
both with cross-linked and non-cross-linked hydrogels. The results show that all the non-
cross-linked formulations show a higher swelling index than the chemically cross-linked
HG, which can be claimed with the hindered diffusion of water into the cross-linked HG
network (Figure 4). The formulation’s property to spread uniformly and easily on an
applied surface is important to deliver a uniform dose of the active compound.
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2.3.4. Viscosity Measurement 
Viscosity is of paramount importance in the case of the applicability of hydrogels to 
the intranasal administration route, which influences the mucoadhesive properties of the 
formulation and can prolong the residence in the nasal cavity. Proper polymer concentra-
tion must be set in order to achieve the desired high viscosity value, allowing increased 
residence time and making it possible to enhance the absorption through the nasal mu-
cosa. However, too high viscosity can also be disadvantageous, resulting in hindered drug 
release of the formulation in the nasal cavity. The viscosity of both cross-linked and non-
cross-linked HGs was measured (Table 2). The viscosity measurement of all formulations 
showed that there was an inverse relation between shear rate and viscosity of HG, which 
proves the thixotropic nature of HGs (Figure 5). No significant differences among viscos-
ities of cross-linked and non-cross-linked HGs was observed. Furthermore, the non-cross 
linked SLNs-HGs were characterized due to the spreadability investigation, where SLNs-
HGnCL formulations showed higher swelling ratio and spreadability, along with the non-
significant difference experienced in the viscosity compared with cross-linked SLNs-HGs. 
Figure 4. Swelling study of optimized cross-linked (SLNs-HGCL) and non-cross-linked (SLNs-
HGnCL) HG (1% w/v HA). Data are means ± SD (n = 3 independent measurements).
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2.3.4. Viscosity Measurement
Viscosity is of paramount importance in the case of the applicability of hydrogels
to the intranasal administration route, which influences the mucoadhesive properties
of the formulation and can prolong the residence in the nasal cavity. Proper polymer
concentration must be set in order to achieve the desired high viscosity value, allowing
increased residence time and making it possible to enhance the absorption through the
nasal mucosa. However, too high viscosity can also be disadvantageous, resulting in
hindered drug release of the formulation in the nasal cavity. The viscosity of both cross-
linked and non-cross-linked HGs was measured (Table 2). The viscosity measurement of
all formulations showed that there was an inverse relation between shear rate and viscosity
of HG, which proves the thixotropic nature of HGs (Figure 5). No significant differences
among viscosities of cross-linked and non-cross-linked HGs was observed. Furthermore,
the non-cross linked SLNs-HGs were characterized due to the spreadability investigation,
where SLNs-HGnCL formulations showed higher swelling ratio and spreadability, along
with the non-significant difference experienced in the viscosity compared with cross-linked
SLNs-HGs.




Figure 5. Viscosity profiles of cross-linked (SLNs-HGCL) and non-cross-linked (SLNs-HGnCL) containing HA in 0.5–1% 
w/v (a) and 2–3% w/v (b) concentration. Data are means ± SD (n = 3 independent measurements).  
2.3.5. In Vitro Mucoadhesion Study 
The in vitro mucoadhesion of HGs was investigated through their displacement on 
an agar-mucin plate. Figure 6 shows that the adhesion potential of HGs at different con-
centrations of HA is inversely related to the displacement of the HG. As the polymer (HA) 
concentration increased, lower displacement was observed on the surface of agar after 7 
h, indicating higher mucoadhesive properties of formulation. This can be related to the 
increasing strength of chemical interactions (secondary bonding) between mucin and HA. 
At the highest concentration (3% w/v) of HA, hardly any displacement was observed dur-
ing the studied time, indicating remarkable mucoadhesion of formulation. At a lower con-
centration (0.5% w/v) of HA, displacement was not adequate for nasal administration, and 
after 2 h it was totally displaced from the agar-mucin plate. Based on these results, the 
optimized concentration of HG (1% w/v) was screened out, as displacement measured at 
this concentration was adequate and also in accordance with the results of viscosity, 
spreadability and swelling ratio measured at this specific concentration, as shown in Table 
2. 
Figure 5. Viscosity profiles of cross-linked (SLNs-HGCL) and non-cross-linked (SLNs-HGnCL) containing HA in 0.5–1%
w/v (a) and 2–3% w/v (b) concentration. Data are means ± SD (n = 3 independent measurements).
2.3.5. In Vitro Mucoadhesion Study
The in vitro mucoadhesion of HGs was investigated through their displacement on
an agar-mucin plate. Figure 6 shows that the adhesion potential of HGs at different
concentrations of HA is inversely related to the displacement of the . As the polymer
(HA) concentration increased, lower displacement was observed on the surface of agar
after 7 h, indicati g higher mucoadhesive properties of formulation. This can be related to
the i cre si strength of chemical interactions (sec ndary b ding) betwe n mucin and
HA. At the highest concentration (3% w/v) of HA, hardly a y displaceme t was observed
during t e studied time, indicating remarkable mucoadhesion of formulation. At a lower
co centra ion (0.5% w/v) of HA, displacem nt was not adequate for nasal administration,
and after 2 h it was totally displaced from the agar-mucin plate. Based on these results,
the optimized concentration of HG (1% w/v) was screened out, as displacem nt measured
at th s concentration was adequate and also in accordance with the results of vi cosity,
spreadability nd s elling ratio measured at this specific concentration, as shown n
Tabl 2.
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2.3.7. In Vitro Permeation
Modified Side-Bi-Side® apparatus was used for the in vitro nasal permeation study,
whereas the diffusion of PG solution, PG-SLNs, as well as TC-P containing and TC-P-free
1% w/v SLNs-HGnCL was compared. The TC-P was used as permeation enhancer due to
its nontoxic and biocompatible nature. Several studies reported its permeation-enhancing
effect through a synthetic membrane and on excised skin, reported in previous studies with
different drugs [31,36–38]. Figure 8a shows the cumulative PG permeation from donor
to acceptor phase through a synthetic cellulose membrane impregnated with isopropyl
myristate. The cumulative permeation of PG from PG-SLNs was ~190 µg/cm2 after 60 min.
The TC-P-free 1% w/v SLNs-HGnCL showed a lower permeation of about 180 µg/cm2,
which supports the advantage of application of permeation enhancer. In the case of pure
PG dispersion, the permeation was lower than 10 µg/cm2. The significantly highest
permeability was achieved with the HG containing TC-P reaching, with a value around
600 µg/cm2.
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2.3.8. In Vitro Release Study
In vitro release studies of PG-SLNs showed burst release of drug in the first 60 min
(~40% of drug) at pH 5.6. After that, the drug release rate decreased following a sustained
release tendency, as shown in Figure 8b. In the case of the HG formulation, the initial
burst effect was lower, which can be claimed with the controlled release effect of the gel
matrix. After 60 min only 15% of PG was released from the HG. To determine the release
kinetic of PG from SLNs as well as HG, various dissolution kinetic models including
zero-order, first-order, Higuchi, Korsmeyer–Peppas and Hixon–Crowel were fitted to the
release data, and kinetic parameters were calculated (Table S1). The drug release both from
SLNs and HG followed Higuchi kinetics (R2 = 0.96 and 0.9783 respectively), which can be
claimed with the drug release controlling mechanism of lipid matrix and swelling ability of
HA-PG matrix in the simulated nasal medium [39]. Fitting the Korsmeyer-Peppas model,
the “n” value was lower than 0.5, which indicates that both formulations follow Fickian
drug diffusion. The significant difference between SLNs and HG can be claimed with the
presence of gel network surrounding the SLNs, which decreases the velocity of Fickian
diffusion, resulting in sustained release of PG.
2.3.9. In Vitro Antioxidant Activity Evaluation with Hydrogen Peroxide Scavenging Assay
The antioxidant activity of PG was investigated, aiming to confirm that PG-SLNs
embedded in HA-HG can preserve antioxidant activity, which is essential in their phar-
macological effect. It has been demonstrated that free radicals have a pivotal role in the
pathogenesis of different diseases, as well as in several types of cancer [40]. The in vitro
scavenging activity of PG-SLN-loaded HA-HGs was investigated containing PG in differ-
ent concentrations utilizing hydrogen peroxide (H2O2) as oxidative medium (Figure 9). It
has been revealed that by increasing the polymer concentration in the HG, the antioxidant
activity of PG against H2O2 was improved, which can be explained by the protective
effect of the hydrogel network. The results also support that a strong correlation could be
found between the concentration of PG and the rate of inhibition of scavenging activity
of H2O2. By increasing the concentration of PG, the inhibition was enhanced. At 10 and
30 µg/mL PG containing HGs (containing 2% and 3% w/v HA), the antioxidant activity
was significantly higher in comparison with low HA concentration HGs and PG-SLNs
or PG control, which also supports the stabilizing effect of the polymer matrix. In the
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case of 20 µg/mL, the same tendency of difference was also demonstrated, but it was
not significant.
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3. Discussion
In our previous work we had already investigated the formulation possibilities of PG-
loaded liposomes coated with HA [41], as PG has advantageous effects (anti-inflammatory,
antioxidant and anticancer activity) in the treatment of brain tumors, e.g., glioblastoma
multiforme. As PG is a water-insoluble compound, loading it into a nanocarrier can
enhance its water solubility and drug release profile in different administration routes. The
present study focused on the formulation of PG-SLNs and loading into HA-HG for brain
targeting through intranasal administration. The novelty of our work lies in the fact that
our research team explored the first-time application of the PG-SLNs-loaded HA-HG for
intranasal delivery route.
SLNs were developed in our study due to their advantageous properties (biocompati-
bility, increased solubility, protection of drug and permeability enhancement) and loaded
into HA-HG as a secondary carrier for facilitating drug transport via the intranasal route.
Due to its mucoadhesive property, the role of HA is vital for intranasal drug delivery
systems because the nasal cavity is subjected to mucociliary clearance [42,43]. TC-P was
utilized as a permeation enhancer as it was previously successfully used as a surfactant
or co-surfactant for intranasal application. TC-P has adequate solubilizing property, and
it has the ability to enhance the drug’s solubility by orders of magnitude compared with
other penetration enhancers.
Aiming to develop novel PG-SLNs-loaded into the HA-HG system, the QbD approach
was applied. After the determination of the QTPP elements, the relations between CQA
and CMA/CPP elements were evaluated, and a risk order was set up based on the software-
calculated severity scores. By optimizing the factors having the highest severity via central
composite design, the optimized SLNs had a Z-average of 120 ± 8.8 nm, with a PDI of
0.12 ± 0.08 and a zeta potential that was a more negative −38 ± 10.2 mV. The indirect and
direct co-effect of cholesterol and Tween 80 on Z-average can be clearly seen in both the
single factor and 3D plot (Figure S2a,b). The results show weak repulsion forces between
lipid nanoparticles and the surfactant at lower concentration of cholesterol. However, at
higher lipid concentrations, prominent repulsion forces can be observed, which can be
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explained by the presence of the surfactant phase between lipid nanoparticles and the
decrease in van der Waals forces, all reducing the aggregation tendency of lipid droplets [44].
The surfactant concentration showed higher impact on the reduction of Z-average and
PDI as compared with cholesterol. These results are in accordance with those reported by
Azhar Shekoufeh Bahari et al. and Severino et al. [39,45]. The low Z-average and narrow
PDI indicate improved nasal absorption, while the highly negative zeta potential due to
surface properties of cholesterol supports high stability of formulation. The absolute value
of zeta potential was higher than 30 mV, which ensures sufficient repulsive forces to attain
better physical and colloidal stability of the nanosystem [46,47]. The morphological studies
by SEM showed spherical shaped SLNs with homogenous distribution and nano-range
particle size.
Raman mapping showed that the increasing concentration of polymer forms well-
designed hydrogel matrix embedding PG-SLNs homogenously, indicating higher stability
of nanoparticles avoiding aggregation [48–50]. The swelling study revealed that the poly-
meric chains were more flexible in cross-linker-free HG, ensuring water diffusion into the
gel matrix.
In the case of chemically cross-linked HG, the free association of the polymer chain is
hindered, resulting in a decreased swelling ratio. From these results, it can be concluded
that by adding a cross-linker, the mechanical strength of the HG was enhanced. More
precise controlled release of the nano-carrier from the gel matrix was reached as com-
pared with simple HG, which is mechanically fragile; thus, larger pores may be created
through which nano-carriers can easily liberate the active substance initiating a burst re-
lease. Previous studies already reported the similar effect of GA with chitosan HG [51–53].
Safety application of GA is based on previous studies, which showed the nose is very
resistant to the aldehydes requiring the application of millimolar concentrations before
toxic responses [30].
Our results indicate the significant potential of TC-P in enhancing the permeation
of PG-SLNs across the artificial cellulose membrane from the HG matrix. TC-P has a
greater influence on the thermodynamic driving force. The maximum thermodynamic
driving force occurring at saturation is based on Fickian diffusion, according to which
the concentration gradient is formed from a high concentration region to a region of
lower concentration phase [36]. TC-P was previously used as a surfactant, co-surfactant
and permeation enhancer for intranasal delivery in different micro- and nanoemulsions.
Several studies demonstrated the influence of TC-P alone or in combination with propylene
glycol on clonazepam permeation both in vitro and ex vivo via application of carbomer
HGs. Mura et al. revealed that applying TC-P in the concentration range of 10–50% w/w
increased skin penetration of the drug [42].
The anticancer activity of PG is based on its antioxidant property of removing free
radicals [54]. The most important mechanism to achieve this goal is to donate hydrogen to
free radicals and convert them into nonreactive species. PG can inhibit cellular damage
mainly through their free radical scavenging property [40]. Therefore, we aimed to evaluate
the antioxidant activity; the hydrogen peroxide (H2O2)-scavenging assay results showed
enhanced antioxidant activity in case of applying PG as well as HA in higher concentrations.
The developed PG-SLNs-loaded HA-HG with the TC-P system, by controlling the drug
release, increasing the physical stability and enhancing the drug permeability via nasal
mucosa while protecting its antioxidant activity, imparts a promising carrier system for the
brain targeting of antioxidant drugs.
4. Materials and Methods
4.1. Materials
PG, the model antioxidant compound, HA (Mw = 14 kDa) and Tween 80 were pur-
chased from Sigma-Aldrich (Budapest, Hungary). Cholesterol, acetone, ethanol (96% v/v),
glutaraldehyde (25% w/v) and sodium chloride for physiological salt solution were pur-
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chased from Molar Chemicals Ltd. (Budapest, Hungary). Transcutol-P (diethyl glycol
monoethyl ether) was supplied by Gattefossé (saint-Priest, France).
4.2. Optimization of SLNs by Quality by Design (QbD) Approach and Risk Assessment Strategy
First, the quality target product profile (QTPP) was defined, followed by selecting the
critical quality attributes (CQAs) and critical process parameters (CPPs). The next step
was to perform the risk assessment (RA) [55–57]. At first, an interdependence rating was
established between the QTPP and CQA elements as well as between CPPs and CQAs.
The RA was conducted using Lean QbD®® software (QbDworks.com, QbD works LLc.,
Fremont. CA, USA). Each factor was thoroughly evaluated on a 3-grade scale using low
(“L”), medium (“M”) and high (“H”) attributives reflecting the relations between the
elements. Based on the interdependence rating, the next step was to quantify the severity
of the risk factors via a probability rating. As a result of the RA, the severity scores of CQAs
and CPPs were plotted on Pareto diagrams generated by the software.
4.3. Response Surface Quadratic Model
Stat-Ease Design Expert® version 10 (stat-Ease, INC.2021 East Hennepin Ave., Suite
480 software) was used to optimize the formulation process and product quality of PG
encapsulated SLNs. The amount of cholesterol (20–60 mg), Tween 80 (10–40 mg) and
temperature (20–70 ◦C) where chosen as independent factors based on the RA process,
while the ratio of aqueous to organic phases (acetone:ethanol) was kept constant (1:4).
Central composite design was applied where SLNs were prepared for each trial, and
three responses were evaluated—namely, average hydrodynamic diameter (Z-average),
polydispersity index (PDI) and zeta potential.
4.4. Development of PG-SLNs by Modified Injection Method
PG-SLNs were prepared through the modified injection method, where 10 mL of
0.2% w/v Tween 80 aqueous solution and 5 mL of the organic phase (ethanol:acetone 4:1)
were added in different ratios. The PG (10 mg) and cholesterol (60 mg) was dissolved
in a mixture of the organic phase and injected dropwise into surfactant solution under
constant stirring at 700 rpm at 70 ◦C. After complete evaporation of the organic phase, the
formulation was purified using a Hermle Z323K high performance refrigerated centrifuge
(Hermle AG, Gossheim, Germany) for 2 h at 13,500 rpm to separate pellets from supernatant
and residual solvent. The collected pellets were redispersed in 5 mL purified water and
freeze-dried using a Scanvac CoolSafe laboratory freeze-dryer (Labogene, Lynge, Denmark)
at −40 ◦C for 12 h under a 0.013 mbar pressure with additional 3 h secondary drying at 25
◦C in presence of 5% w/v trehalose as cryoprotectant to obtain lyophilized powders. The
lyophilized powder was stored at 5 ± 3 ◦C until further investigation.
4.5. Preparation of Mucoadhesive HA-Based Hydrogel Formulations with PG-SLNs
Different concentrations (0.5, 1, 2 and 3 w/v) of HA were used to prepare colloidal HA-
HGs, dissolving them in water for half an hour at 400 rpm. After complete swelling of the
HA, the freeze-dried SLNs and 0.1% w/v glutaraldehyde as cross-linker were added into
the HA to form an acetal bond among the aldehyde and hydroxyl group by maintaining
acidic conditions. After the reaction, 1 mL of TC-P, as permeation enhancer, was added to
the HGs.
4.6. Characterization of PG-SLNs
4.6.1. X-ray Powder Diffraction (XRPD)
Structural characterization of PG-SLNs was performed using a BRUKER D8 Advance
X-ray powder diffractometer (Bruker AXS GmbH, Karlsruhe, Germany). All the compo-
nents and formulations were analyzed in a quartz sample holder and were scanned at
40 kV and 40 mA with Cu K λI radiation (λ = 1.5406 Å) using a VANTEC-1 slit detector in
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the angular range of 3◦ to 40◦ 2θ, at a step time of 0.1 s and an increment of 0.007◦. Each
measurement was carried out at ambient humidity and temperature.
4.6.2. Fourier-Transformed Infrared Spectroscopy (FTIR)
The compatibility and interactions between PG and the components of the formulation
were investigated using a Thermo Nicolet AVATAR FTIR instrument (Thermo-Fisher,
Waltham, MA, USA). For the investigation, pellets were prepared by co-grinding 10 mg
compound with 150 mg potassium bromide (KBr) and compressed with 10 tons using a
hydraulic press. The FTIR spectra were measured over the range of 4000–400 cm−1 with a
resolution of 4 cm−1 for 128 scans. The recorded spectra were reported as absorbance as a
function of wavenumber.
4.6.3. Measurement of Z-Average, Surface Charge and Polydispersity Index
The measured amount (6 mg) of lyophilized SLNs was reconstituted in 6 mL of purified
water and sonicated for 4 min to minimize the inter-particle aggregation. The Z-average, PDI
and surface charge (zeta potential) of PG-SLNs were measured in folded capillary cells using
a Malvern Zetasizer nano ZS instrument (Malvern Instrument, Worcestershire, UK) at 25 ◦C,
with the refractive index 1.445. All the measurements were conducted in triplicate, and
data are presented as average ± SD.
4.6.4. Encapsulation Efficiency (EE), Loading Capacity (LC) and Percentage
Yield Determination
EE and LC of PG-SLNs were determined using an indirect method. PG-SLNs were
first centrifuged for 1 h at 16,500 rpm at 4 ◦C in a Hermle laboratory centrifuge (Hermle
AG, Gosheim, Germany). The supernatant was collected and diluted 10-fold with purified
water. The concentration of PG was determined using HPLC. The EE, as the actual PG
content in the optimized formulation, was measured according to the following equation:




where w1 is the total amount of added PG, and w2 is the amount of free PG in the supernatant.
The LC was calculated via the following equation:




where w1 is the total amount of added PG, and w2 is the amount of free PG in the super-
natant, while w3 is the total amount of lipid added to the formulation.
The percentage yield was calculated by weighing the dried PG-SLNs and determined
by using the following formula [58]:
Percentage yield (%) =
weight of dried NPs
theoretical weight of drug and components
× 100 (6)
4.6.5. HPLC Method
The PG quantification was carried via HPLC (Agilent 1260, agent technologies, Santa
Clara, CA, USA). The stationary phase was C18 column (Gemini-NX® 150 mm × 4.6 mm,
5 µm (Phenomenex, Torrance, CA, USA). Purified water and acetonitrile in 80:20 ratio
adjusted pH = 3.0, with phosphoric acid used as mobile phase. A set of 20 µL samples
were injected, whereas separation was performed by 10 min isocratic elution at 25 ◦C
temperature with 1 mL/min eluent flow. The UV-Vis diode array detector was applied for
the detection of chromatograms at 254 nm. ChemStation B.04.03 Software (Santa Clara,
CA, USA) was used for evaluation of data. PG retention time was detected at 4 min. For
the calibration line, the linear regression was 0.998. The quantification limit (LOQ) and
detection (LOD) of PG were 63 ppm and 21 ppm, respectively [41,59].
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4.7. Characterization of PG-SLNs Loaded Hydrogels
4.7.1. Physical Appearance, pH and Drug Contents of Hydrogels
PG-SLN HGs containing HA in different concentrations (0.5, 1, 2 and 3% w/v) were
evaluated apparently for grittiness and uniformity. The pH of HGs was measured directly
by dipping pH meter (WTW® inoLab® pH 7110 laboratory pH tester, Thermo Fisher
Scientific, Budapest, Hungary). To determine the drug contents in the formulation, 1 g of
HG was dispersed in 10 mL of phosphate buffer (pH 7.4). This diluted gel was filtered with
a membrane filter (0.45 µm, polypropylene) and analyzed by HPLC. All measurements
were carried out in triplicate. Drug content was evaluated by the following formula:
Percent Drug contents =
Actual amount of drug in the formulation
Theoretical amount of drug in thr formualtion
× 100 (7)
4.7.2. Raman Spectroscopy
A Thermo Fisher DXR Dispersive Raman instrument (Thermo Fisher Scientific Inc.,
Waltham, MA, USA) was used for investigation of SLNs. This instrument was equipped
with a 780 nm wavelength diode laser and a CCD camera. The laser power of 12 mW at
50 µm slit aperture size was used for Raman measurements with 2 and 6 s of exposure and
acquisition time, for a total of 32 scans per spectrum in the spectral range 3500–200 cm−1
with fluorescence and cosmic ray corrections. The PG-SLNs distribution in HGs was
determined via Raman chemical mapping in the formulation. For the total of 16 scans,
a 45 µm × 45 µm size surface was evaluated with a 10 µm step size. To eliminate the
intensity deviation between the measured areas, the normalization of Raman spectra was
ensured [60].
4.7.3. Swelling Index
To measure the swelling index of the HGs, the gravimetric method was applied.
Lyophilized gel of both cross-linked and non-cross-linked HGs was soaked in phosphate
buffer saline (PBS) (pH = 7.4). After swelling, HGs were taken out from the medium and
weighed at different time intervals (after every 30 min) until the weight of the swelled HG





where w1 is the initial weight of hydrogel, and w2 is the weight of swollen HG after each
sampling point.
4.7.4. Spreadability Test
Spreadability of HGs was measured using the glass slide method. The center of the
glass slide was marked with a 1 cm diameter circle upon which 0.5 g of gel was placed.
Another glass slide was placed over the HG, forming a sandwich arrangement. The
load of the 500 g was placed on the upper plate and weighted for 5 min. After 5 min,
the load was removed, and the increment in HG diameter was measured [61]. All the
results were evaluated with respect to the spreading area and applied weight by using the
following equation:




where Si is the swelling index, d the diameter of the glass slide and π the shear stress.
4.7.5. Viscosity Measurement
Viscosity measurement was performed at 37 ◦C with a Haake Rheostress 1 instrument
(Thermo Scientific, Karlsruhe, Germany). A cone-plate device was used where the cone
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diameter was 6 cm with an angle of 1◦ and a 0.052 mm gap size. The apparent viscosity
curves of the samples were plotted under the shear rate range of 0.01–100 s−1.
4.8. In Vitro Characterization of Nanoparticles and Hydrogel
4.8.1. In Vitro Mucoadhesion Testing
In vitro mucoadhesion was performed using the displacement method. A specified
weighted amount (5 mg) of HG for each respective HA concentration (0.5, 1, 2 and 3% w/v)
was placed on the top of 1% w/v agar and 2% w/v mucin aqueous solution casted on a glass
plate of 9 cm and was inclined at 60◦ in an incubator at 37 ◦C. The downward movement
of the HG mass was measured in millimeters hourly up to 7 h. All the measurements were
conducted in triplicate [61,62].
4.8.2. Surface Morphology
Scanning electron microscopy (SEM) (Hitachi S4700, Hitachi Scientific Ltd., Tokyo,
Japan) was used to characterize the morphology and surface properties of both PG-SLNs-
lyophilized formulation and PG-SLNs-loaded HG. A voltage of 10 kV and 10 mA amperage
was applied at 1.3–13.1 mPa pressure. A greater vacuum evaporator and argon atmosphere
were used to make the sputter-coated samples conductive with gold–palladium (Bio-
Rad SC 502, VG Microtech, Uckfield, UK). The gold–palladium coating thickness was
approximately 10 nm.
4.8.3. In Vitro Permeation Study
A modified horizontal side-by-side type diffusion apparatus was used for in vitro
permeation studies at 37 ◦C and with 100 rpm constant stirring (Thermo Haake C10-P5,
Sigma-Aldrich Co. LLC, St. Louis, MO, USA). The donor and receptor compartments
were isolated with an isopropyl myristate impregnated artificial membrane (0.45 µm pore
size, Pall Metri-cel cellulose membrane) with a 0.69 cm2 diffusion surface. The donor
compartment consisted of 9 mL simulated nasal electrolyte solution (SNES) with a pH
of 5.6, which contained 0.59 g CaCl2, 8.77 g NaCl, 2.98 g KCl anhydrous in 1000 mL of
deionized water, where the acceptor compartment consisted of pH 7.4 PBS. The measured
amount (5 mg) of formulation was placed in the donor phase 1 mL of each sample (PG,
PG-SLNs, PG-SLNs-loaded HG with and without TC-P) and was withdrawn from the
acceptor phase every 5 min and replaced with the same volume of fresh medium. The
amount of the drug diffused through the membrane was quantified by using HPLC. Each
formulation was analyzed in triplicate.
4.8.4. In Vitro Release Study
The in vitro dissolution study was performed under the nasal conditions at 37 ◦C by
using the modified paddle method with a Hanson SR8 Plus apparatus (Teledyne Hanson
Research, Chatsworth, CA, USA) at 50 rpm constant stirring. The PG (10 mg) containing
formulation was placed into 50 mL SNES (pH 5.60) as dissolution medium, and samples
were withdrawn in predetermined time intervals of 5, 15, 30, 60, 180, 360 and 720 min. After
filtration (0.45 µm membrane filter), the PG concentration of the aliquots was analyzed
using HPLC. All the measurements were performed in triplicate. The in vitro drug release
kinetics of each sample were also evaluated, fitting various mathematical models—namely,
zero-order, first-order, Higuchi, Korsmeyer–Peppas and Hixon–Crowel models.
4.8.5. Hydrogen Peroxide Scavenging (H2O2) Assay
A solution of hydrogen peroxide (40 mM) was prepared in 0.05 M phosphate buffer
(pH 7.4). PG SLNs with different drug concentrations (10, 20 and 30 µg/mL) were incor-
porated in a 0.6 mL and 40 mM hydrogen peroxide solution. After 10 min of addition
of hydrogen peroxide, the absorbance at wavelength of 230 nm was determined spec-
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trophotometrically using phosphate buffer as reference [40,61,63]. The hydrogen peroxide
percentage scavenging activity was then measured using the following formula:




where Ao is the absorbance of the control reaction, and A is the absorbance in the presence
of initial PG containing sample.
4.9. Statistical Analysis
The statistical analysis was applied to all the results using Microsoft® 13 software
(SAS Institute, Cary, NC, USA). All the results were repeated in triplicate, and the means
of data are expressed with standard deviation. In vitro permeation and release data were
compared using the one-way analysis of variance (ANOVA); differences were considered
significant when p < 0.05.
5. Conclusions
PG-SLNs were successfully prepared using a modified injection method. For the
optimization of formulation and process parameters affecting the quality of the nanosystem,
the initial risk assessment study and the design of experiment were applied following the
QbD approach. The addition of PG endowed the HG with the ability to facilitate anticancer
activity and with significant potential to be co-encapsulated with other anti-glioblastoma
drugs. Our optimized platform provided in vitro proof of the potential of combining the
advantages of lipid-based NPs with HG as a promising intranasal delivery system.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ph14070696/s1, Figure S1: Interdependence rating amongst QTPP—CQA (a) and CPP/CMA—
CQA (b) elements, Figure S2: 3D surface plot (a) and one-factor interaction (b) graph showing
the effects of surfactant and cholesterol on Particle Size, PDI and Zeta potential, Table S1: Kinetic
parameters of in vitro drug release.
Author Contributions: Conceptualization, F.S., G.K. and I.C.; methodology, F.S., G.K., B.S. and
I.C.; software, F.S., G.K. and B.S.; validation, G.K. and I.C.; formal analysis, G.K., R.I. and I.C.;
investigation, F.S., G.K. and R.A.; resources, I.C.; data curation, F.S., G.K. and B.S.; writing—original
draft preparation, F.S.; writing—review and editing, G.K., R.I. and I.C.; visualization, F.S. and G.K.;
supervision, I.C.; project administration, I.C.; funding acquisition, I.C. All authors have read and
agreed to the published version of the manuscript.
Funding: The publication was funded by The University of Szeged Open Access Fund (FundRef,
Grant No. 5349).
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Data is contained within the article and supplementary material.
Acknowledgments: The authors want to express their acknowledgment to the supporters. This
study was supported by the Ministry of Human Capacities, Hungary (Grant TKP-2020), and by the
National Research, Development and Innovation Office, Hungary (GINOP 2.3.2-15-2016-00060).
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
ANOVA one-way analysis of variance
BBB blood–brain barrier
CNS central nervous system
Pharmaceuticals 2021, 14, 696 18 of 21
CPPs critical process parameters
CMA critical materials attributes
CQA critical quality attributes
CCD central composite design
◦C centigrade
EE encapsulation efficiency





HPLC high proficiency liquid chromatography
H2O2 hydrogen peroxide




LOQ limit of quantification









ppm parts per million
PBS phosphate buffer saline
PG propyl gallate
PG-SLNs PG-solid lipid nanoparticles
PDI polydispersity index
Pas pascal
QbD Quality by Design
QTPP quality target product profile
RA risk assessment
SLNs solid lipid nanoparticles
SEM scanning electron microscopy
SLNs-HGnCL SLNs non-cross-linked HG




XRPD X-ray powder diffractograms
References
1. Chung, E.P.; Cotter, J.D.; Prakapenka, A.V.; Cook, R.L.; Diperna, D.M.; Sirianni, R.W. Targeting small molecule delivery to
the brain and spinal cord via intranasal administration of rabies virus glycoprotein (RVG29)-modified PLGA nanoparticles.
Pharmaceutics 2020, 12, 93. [CrossRef]
2. Gonçalves, J.; Bicker, J.; Gouveia, F.; Liberal, J.; Oliveira, R.C.; Alves, G.; Falcão, A.; Fortuna, A. Nose-to-brain delivery of
levetiracetam after intranasal administration to mice. Int. J. Pharm. 2019, 564, 329–339. [CrossRef] [PubMed]
3. Kanazawa, T.; Kaneko, M.; Niide, T.; Akiyama, F.; Kakizaki, S.; Ibaraki, H.; Shiraishi, S.; Takashima, Y.; Suzuki, T.; Seta, Y.
Enhancement of nose-to-brain delivery of hydrophilic macromolecules with stearate- or polyethylene glycol-modified arginine-
rich peptide. Int. J. Pharm. 2017, 530, 195–200. [CrossRef] [PubMed]
4. Ullah, I.; Chung, K.; Bae, S.; Li, Y.; Kim, C.; Choi, B.; Nam, H.Y.; Kim, S.H.; Yun, C.O.; Lee, K.Y.; et al. Nose-to-Brain Delivery of
Cancer-Targeting Paclitaxel-Loaded Nanoparticles Potentiates Antitumor Effects in Malignant Glioblastoma. Mol. Pharm. 2020,
17, 1193–1204. [CrossRef] [PubMed]
Pharmaceuticals 2021, 14, 696 19 of 21
5. Ul Islam, S.; Shehzad, A.; Bilal Ahmed, M.; Lee, Y.S. Intranasal delivery of nanoformulations: A potential way of treatment for
neurological disorders. Molecules 2020, 25, 1929. [CrossRef] [PubMed]
6. Sintov, A.C. AmyloLipid Nanovesicles: A self-assembled lipid-modified starch hybrid system constructed for direct nose-to-brain
delivery of curcumin. Int. J. Pharm. 2020, 588, 119725. [CrossRef] [PubMed]
7. Sabir, F.; Ismail, R.; Csoka, I. Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: Status
quo and outlook. Drug Discov. Today 2020, 25, 185–194. [CrossRef]
8. Agrawal, M.; Konwar, A.N.; Alexander, A.; Borse, V. Nose-to-brain delivery of biologics and stem cells. In Direct Nose-To-brain
Drug Delivery; Elsevier: Amsterdam, The Netherlands, 2021; pp. 305–328. [CrossRef]
9. Madav, Y.; Wairkar, S. Strategies for enhanced direct nose-to-brain drug delivery. In Direct Nose-to-Brain Drug Delivery; Elsevier:
Amsterdam, The Netherlands, 2021; pp. 169–184. [CrossRef]
10. Pardeshi, C.V.; Souto, E.B. Surface modification of nanocarriers as a strategy to enhance the direct nose-to-brain drug delivery. In
Direct Nose-to-Brain Drug Delivery; Elsevier: Amsterdam, The Netherlands, 2021; pp. 93–114. [CrossRef]
11. Battaglia, L.; Panciani, P.P.; Muntoni, E.; Capucchio, M.T.; Biasibetti, E.; De Bonis, P.; Mioletti, S.; Fontanella, M.; Swaminathan,
S. Lipid nanoparticles for intranasal administration: Application to nose-to-brain delivery. Expert Opin. Drug Deliv. 2018, 15,
369–378. [CrossRef]
12. Kadam, T.S.; Agrawal, A. Short Review on the Important Aspects Involved in Preparation, Characterization and Application of
Nanostructured Lipid Carriers for Drug Delivery. Curr. Nanomed. 2020, 10, 188–207. [CrossRef]
13. Mahmood, H.S.; Alaayedi, M.; Ashoor, J.A.; Alghurabi, H. The enhancement effect of olive and almond oils on permeability of
nimesulide as transdermal gel. Int. J. Pharm. Res. 2019, 11, 1200–1206.
14. Fytianos, G.; Rahdar, A.; Kyzas, G.Z. Nanomaterials in cosmetics: Recent updates. Nanomaterials 2020, 10, 979. [CrossRef]
15. Yasir, M.; Sara, U.V.S.; Chauhan, I.; Gaur, P.K.; Singh, A.P.; Puri, D.; Ameeduzzafar, A. Solid lipid nanoparticles for nose to brain
delivery of donepezil: Formulation, optimization by Box–Behnken design, in vitro and in vivo evaluation. Artif. Cells, Nanomed.
Biotechnol. 2018, 46, 1838–1851. [CrossRef]
16. Vasvani, S.; Kulkarni, P.; Rawtani, D. Hyaluronic acid: A review on its biology, aspects of drug delivery, route of administrations
and a special emphasis on its approved marketed products and recent clinical studies. Int. J. Biol. Macromol. 2020, 151, 1012–1029.
[CrossRef] [PubMed]
17. Taymouri, S.; Shahnamnia, S.; Mesripour, A.; Varshosaz, J. In vitro and in vivo evaluation of an ionic sensitive in situ gel
containing nanotransfersomes for aripiprazole nasal delivery. Pharm. Dev. and Tech. 2021. just-accepted. [CrossRef]
18. Zhang, H.; Fan, T.; Chen, W.; Li, Y.; Wang, B. Recent advances of two-dimensional materials in smart drug delivery nano-systems.
Bioact. Mater. 2020, 5, 1071–1086. [CrossRef]
19. Thompson, C.M.; Gentry, R.; Fitch, S.; Lu, K.; Clewell, H.J. An updated mode of action and human relevance framework
evaluation for Formaldehyde-Related nasal tumors. Crit. Rev. Toxicol. 2020, 50, 919–952. [CrossRef] [PubMed]
20. Huang, H.M.; Wu, P.H.; Chou, P.C.; Hsiao, W.T.; Wang, H.T.; Chiang, H.P.; Lee, C.M.; Wang, S.H.; Hsiao, Y.C. Enhancement of
T2* weighted MRI imaging sensitivity of U87MG glioblastoma cells using γ-ray irradiated low molecular weight hyaluronic
acid-conjugated iron nanoparticles. Int. J. Nanomed. 2021, 16, 3789–3802. [CrossRef] [PubMed]
21. Khorsandi, L.; Mansouri, E.; Rashno, M.; Karami, M.A.; Ashtari, A. Myricetin Loaded Solid Lipid Nanoparticles Upregulate
MLKL and RIPK3 in Human Lung Adenocarcinoma. Int. J. Pept. Res. Ther. 2020, 26, 899–910. [CrossRef]
22. Hadavi, R.; Jafari, S.M.; Katouzian, I. Nanoliposomal encapsulation of saffron bioactive compounds; characterization and
optimization. Int. J. Biol. Macromol. 2020, 164, 4046–4053. [CrossRef]
23. Salmanzadeh, R.; Eskandani, M.; Mokhtarzadeh, A.; Vandghanooni, S.; Ilghami, R.; Maleki, H.; Saeeidi, N.; Omidi, Y. Propyl
gallate (PG) and tert-butylhydroquinone (TBHQ) may alter the potential anti-cancer behavior of probiotics. Food Biosci. 2018, 24,
37–45. [CrossRef]
24. Detsi, A.; Kavetsou, E.; Kostopoulou, I.; Pitterou, I.; Pontillo, A.R.N.; Tzani, A.; Christodoulou, P.; Siliachli, A.; Zoumpoulakis, P.
Nanosystems for the encapsulation of natural products: The case of chitosan biopolymer as a matrix. Pharmaceutics 2020, 12, 669.
[CrossRef]
25. Yang, J.T.; Lee, I.N.; Lu, F.J.; Chung, C.Y.; Lee, M.H.; Cheng, Y.C.; Chen, K.T.; Chen, C.H. Propyl Gallate Exerts an Antimigration
Effect on Temozolomide-Treated Malignant Glioma Cells through Inhibition of ROS and the NF- κ B Pathway. J. Immunol. Res.
2017, 2017. [CrossRef]
26. Stocker, E.; Becker, K.; Hate, S.; Hohl, R.; Schiemenz, W.; Sacher, S.; Zimmer, A.; Salar-Behzadi, S. Application of ICH Q9 Quality
Risk Management Tools for Advanced Development of Hot Melt Coated Multiparticulate Systems. J. Pharm. Sci. 2017, 106,
278–290. [CrossRef]
27. ICH. Pharmaceutical Development Q8; ICH Harmonised Tripartite Guideline; ICH: Geneva, Switzerland, 2009; pp. 1–28.
28. Németh, Z.; Pallagi, E.; Dobó, D.G.; Csóka, I. A proposed methodology for a risk assessment-based liposome development
process. Pharmaceutics 2020, 12, 1164. [CrossRef]
29. Pallagi, E.; Jójárt-Laczkovich, O.; Németh, Z.; Szabó-Révész, P.; Csóka, I. Application of the QbD-based approach in the early
development of liposomes for nasal administration. Int. J. Pharm. 2019, 562, 11–22. [CrossRef]
30. McGregor, D.; Bolt, H.; Cogliano, V.; Richter-Reichhelm, H.B. Formaldehyde and glutaraldehyde and nasal cytotoxicity: Case
study within the context of the 2006 IPCS human framework for the analysis of a cancer mode of action for humans. Crit. Rev.
Toxicol. 2006, 36, 821–835. [CrossRef]
Pharmaceuticals 2021, 14, 696 20 of 21
31. Pillai, A.M.; Sivasankarapillai, V.S.; Rahdar, A.; Joseph, J.; Sadeghfar, F.; Anuf, A.R.; Rajesh, K.; Kyzas, G.Z. Green synthesis
and characterization of zinc oxide nanoparticles with antibacterial and antifungal activity. J. Mol. Struct. 2020, 1211, 128107.
[CrossRef]
32. Mertins, O.; Mathews, P.D.; Angelova, A. Advances in the design of ph-sensitive cubosome liquid crystalline nanocarriers for
drug delivery applications. Nanomaterials 2020, 10, 963. [CrossRef] [PubMed]
33. Rajesh, S.; Zhai, J.; Drummond, C.J.; Tran, N. Synthetic ionizable aminolipids induce a pH dependent inverse hexagonal to
bicontinuous cubic lyotropic liquid crystalline phase transition in monoolein nanoparticles. J. Colloid Interface Sci. 2021, 589, 85–95.
[CrossRef]
34. Hao, J.; Zhao, J.; Zhang, S.; Tong, T.; Zhuang, Q.; Jin, K.; Chen, W.; Tang, H. Fabrication of an ionic-sensitive in situ gel loaded
with resveratrol nanosuspensions intended for direct nose-to-brain delivery. Colloids Surfaces B Biointerfaces 2016, 147, 376–386.
[CrossRef] [PubMed]
35. Khatoon, M.; Sohail, M.F.; Shahnaz, G.; ur Rehman, F.; Fakhar-ud-Din; ur Rehman, A.; Ullah, N.; Amin, U.; Khan, G.M.; Shah,
K.U. Development and Evaluation of Optimized Thiolated Chitosan Proniosomal Gel Containing Duloxetine for Intranasal
Delivery. AAPS PharmSciTech 2019, 20. [CrossRef] [PubMed]
36. Osborne, D.W.; Musakhanian, J. Skin Penetration and Permeation Properties of Transcutol®—Neat or Diluted Mixtures. AAPS
PharmSciTech 2018, 19, 3512–3533. [CrossRef] [PubMed]
37. Chin, L.Y.; Tan, J.Y.P.; Choudhury, H.; Pandey, M.; Sisinthy, S.P.; Gorain, B. Development and optimization of chitosan coated
nanoemulgel of telmisartan for intranasal delivery: A comparative study. J. Drug Deliv. Sci. Technol. 2021, 62, 102341. [CrossRef]
38. Sivasankarapillai, V.S.; Das, S.S.; Sabir, F.; Sundaramahalingam, M.A.; Colmenares, J.C.; Prasannakumar, S.; Rajan, M.; Rahdar, A.;
Kyzas, G.Z. Progress in natural polymer engineered biomaterials for transdermal drug delivery systems. Mater. Today Chem. 2021,
19, 100382. [CrossRef]
39. Varma, L.T.; Singh, N.; Gorain, B.; Choudhury, H.; Tambuwala, M.M.; Kesharwani, P.; Shukla, R. Recent Advances in Self-
Assembled Nanoparticles for Drug Delivery. Curr. Drug Deliv. 2020, 17, 279–291. [CrossRef]
40. Al-Amiery, A.A.; Al-Majedy, Y.K.; Kadhum, A.A.H.; Mohamad, A.B. Hydrogen peroxide scavenging activity of novel coumarins
synthesized using different approaches. PLoS ONE 2015, 10, e0132175. [CrossRef]
41. Sabir, F.; Katona, G.; Pallagi, E.; Dobó, D.G.; Akel, H.; Berkesi, D.; Kónya, Z.; Csóka, I. Quality-by-Design-Based Development of
n-Propyl-Gallate-Loaded Hyaluronic-Acid-Coated Liposomes for Intranasal Administration. Molecules 2021, 26, 1429. [CrossRef]
42. Javadzadeh, Y.; Adibkia, K.; Hamishekar, H. Transcutol® (Diethylene Glycol). In Percutaneous Penetration Enhancers Chemical
Methods in Penetration Enhancement: Modification of the Stratum Corneum; Springer: Berlin/Heidelberg, Germany, 2015; pp. 195–205.
[CrossRef]
43. Khan, A.; Aqil, M.; Imam, S.S.; Ahad, A.; Sultana, Y.; Ali, A.; Khan, K. Temozolomide loaded nano lipid based chitosan hydrogel
for nose to brain delivery: Characterization, nasal absorption, histopathology and cell line study. Int. J. Biol. Macromol. 2018, 116,
1260–1267. [CrossRef] [PubMed]
44. Tapeinos, C.; Battaglini, M.; Ciofani, G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for
targeting brain diseases. J. Control. Release 2017, 264, 306–332. [CrossRef]
45. Bahari, L.A.S.; Hamishehkar, H. The impact of variables on particle size of solid lipid nanoparticles and nanostructured lipid
carriers; A comparative literature review. Adv. Pharm. Bull. 2016, 6, 143–151. [CrossRef]
46. Sarhadi, S.; Gholizadeh, M.; Moghadasian, T.; Golmohammadzadeh, S. Moisturizing effects of solid lipid nanoparticles (SLN)
and nanostructured lipid carriers (NLC) using deionized and magnetized water by in vivo and in vitro methods. Iran. J. Basic
Med. Sci. 2020, 23, 337–343. [CrossRef]
47. Naseri, M.; Golmohamadzadeh, S.; Arouiee, H.; Jaafari, M.R.; Nemati, S.H. Preparation and comparison of various formulations
of solid lipid nanoparticles (SLNs) containing essential oil of Zataria multiflora. J. Hortic. Postharvest Res. 2020, 3, 73–84.
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